Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Altered Mental Status, Sepsis, Heart Failure, Hemorrhage, Respiratory Distress Syndrome, Adult, Cardiac Arrest
Interventions: 731 Series Ventilator; Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 5
States / cities: Hartford, Connecticut • Baton Rouge, Louisiana • Uxbridge, Massachusetts + 2 more

Conditions: Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 12,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pneumonia, Necrotizing Soft Tissue Infection, Intraabdominal Infections, Infection Joint
Interventions: Blue Light; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: CVC Train the Trainer; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postoperative Wound Infection-deep, Post Operative Wound Infection
Interventions: RUT058-60, Sterile saline for irrigation; Drug
Lead sponsor: Pulmatrix Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Mobile, Alabama • La Jolla, California • Houston, Texas + 1 more

Conditions: HIV Infections
Interventions: Tipranavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 28 more

Conditions: Central Line-associated Bloodstream Infection (CLABSI), Ventilator Associated Pneumonia
Interventions: Collaborative Group, Tool Kit; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Year and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Acute Respiratory Distress Syndrome, Sepsis, Cardiovascular Shock
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 9 Years to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Gram-negative Bacteremia, Bacteremia
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Kidney Injury, Septic Shock, Resuscitations
Interventions: Abdominal Perfusion Pressure (APP), Mean Arterial Pressure (MAP); Device
Lead sponsor: Potrero Medical; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Little Rock, Arkansas • Atlanta, Georgia

Conditions: MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
Interventions: Exebacase; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Butte, Montana • Toledo, Ohio

Conditions: Septicemia
Interventions: Biospecimen Collection; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis
Interventions: Near-real time automated feedback on SEP-1 performance; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Septic Shock
Interventions: Angiotensin II; Drug
Lead sponsor: George Washington University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Intraventricular Hemorrhage, Late Onset Neonatal Sepsis, Motor Skills Disorders
Interventions: delayed cord clamping; Procedure
Lead sponsor: University of Rhode Island; Other
Eligibility: Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Persistent Fetal Circulation Syndrome, Diaphragmatic Hernia, Meconium Aspiration, Sepsis
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Day to 30 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endocarditis, Bacterial, Infective Endocarditis
Interventions: daptomycin, vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Greenville, North Carolina • Cleveland, Ohio

Conditions: Infections, Bacterial, Sepsis, Alert Fatigue, Health Personnel
Interventions: Epic Best Practice Alert; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sepsis, Severe, Septic Shock
Interventions: Smoflipid; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions: beta-glucan, rituximab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Pre-hospital Ventilation Clinical Study

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

Central Venous Catheter Insertion Train the Trainer

A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Safe Critical Care: Testing Improvement Strategies

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis

Clinical Outcomes and Cost of Gram Negative Bacteremia

Targeting Abdominal Perfusion Pressure in Septic Shock

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Correlating MicroRNA Changes With Sepsis Outcomes

Using AI to Improve Sepsis Quality of Care in the Emergency Department

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

Effects of Delayed Cord Clamping in Very Low Birth Weight Infants

Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial

LIPIDS-P Trial Phase I/II Trial

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation